Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statistical Guardrails for Hybrid-Controlled Trials: Robust to Confounding and Between-Study Heterogeneity.

Therapeutic innovation & regulatory science·2026
Same author

Cure Models: What is Meant by a Survival 'Plateau', and Do Experts Agree on What Constitutes One?

PharmacoEconomics·2025
Same author

A Response to the Letter to the Editor: "Decision Trees and Random Forests: Nonlinear and Nonparametric Alternatives to Logistic Regression in Biological Data Analysis".

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2025
Same author

Evaluation of Optimal Cut-Offs and Dichotomous Combinations for Two Biomarkers to Improve Patient Selection.

Therapeutic innovation & regulatory science·2025
Same author

Worldwide Incidence and Mortality of Biliary Tract Cancer.

Gastro hep advances·2024
Same author

Biomarkers for Precision Patient Selection in Cancer Therapy Approvals in the US, from 2011 to 2023.

Clinical pharmacology and therapeutics·2024

Related Experiment Video

Updated: May 11, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.7K

Biomarker-Driven Oncology Trial Design and Subgroup Characterization: Challenges and Potential Solutions.

Jian Wang1, Binbing Yu2, Yannan Nancy Dou1

  • 1Oncology Regulatory Science, Strategy & Excellence, AstraZeneca, Gaithersburg, MD.

JCO Precision Oncology
|June 7, 2024
PubMed
Summary

Biomarker-guided oncology trials can improve drug development efficiency. Analyzing past approvals reveals key factors for regulatory benefit-risk assessments in biomarker-defined subgroups versus all-comers.

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

651
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.0K

Related Experiment Videos

Last Updated: May 11, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.7K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

651
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.0K

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Biomarker Development

Background:

  • Biomarkers are crucial for selecting patient populations likely to benefit from cancer therapies, enhancing clinical trial efficiency.
  • Many oncology drugs approved by the US Food and Drug Administration (FDA) were initially tested in broad patient groups but later restricted to biomarker-defined subgroups.

Purpose of the Study:

  • To analyze FDA-approved oncology therapeutics tested in "all-comers" populations but approved for biomarker-defined subgroups.
  • To identify critical factors for regulatory benefit-risk assessments comparing biomarker-defined subgroups to all-comers approvals.
  • To propose a decision tree for optimizing clinical trial design using patient enrichment and stratification strategies.

Main Methods:

  • Review of pivotal trials for oncology therapeutics with "all-comers" designs that resulted in biomarker-defined subgroup approvals.
  • Analysis of key considerations for regulatory benefit-risk assessments: biological/clinical rationale, biomarker prevalence, safety, trial design, and subgroup efficacy.
  • Development of a decision tree for clinical trial design, incorporating marker type, prevalence, and assay logistics.
  • Recommendation for prespecifying clinically meaningful improvement in biomarker-negative subgroups and using Bayesian methods for evidence integration.

Main Results:

  • Favorable benefit-risk assessments were often established in biomarker-positive subgroups, even when trials included all-comers.
  • Key factors influencing regulatory decisions include biological rationale, biomarker prevalence, safety data, and efficacy within subgroups.
  • A decision tree is proposed to guide the choice between patient enrichment and stratification based on various factors.

Conclusions:

  • Optimizing biomarker-driven drug development in oncology requires innovative clinical trial designs, robust statistical methodologies, and careful regulatory considerations.
  • Strategic use of biomarkers can enhance the efficiency and success rate of oncology drug development.
  • The analysis provides a framework for regulatory benefit-risk assessments and clinical trial design in the era of precision oncology.